CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
UK life sciences bodies submit concerns over ‘no deal’ Brexit
Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Hikma and Vectura collaborate to develop GSK generics
Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.
BMS company not required to pay damages in trade secrets case
A jury has said that Flexus Biosciences, a company owned by Bristol-Myers Squibb, does not need to pay damages despite being liable for trade secrets misappropriation.
Roche, Boehringer and AbbVie have strong pot portfolios: report
The strongest cannabidiol patent portfolios are owned by Roche, Boehringer Ingelheim, and AbbVie, according to a report released earlier this week.
EPO revokes Bayer broccoli patent
The European Patent Office has revoked a Bayer-owned patent which covers a type of broccoli adapted to make their harvesting easier.
AbbVie and Momenta announce Humira patent licence agreement
Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
Swiss IP office issues SPC clarification
The Swiss Federal Institute of Intellectual Property has issued a notice covering a change in the practice for granting supplementary protection certificates (SPCs), following a landmark decision by Switzerland’s highest court.
Womble adds McCarter patent attorney in Boston
Womble Bond Dickinson has strengthened its Boston-based life sciences team with the addition of patent attorney Briana Erickson.
Teva and Mylan implore Fed Circuit not to stay immunity ruling
Generic makers Teva, Mylan and Akorn asked the US Court of Appeals for the Federal Circuit not to stay to its sovereign immunity ruling pending an appeal by Allergan and the Saint Regis Mohawk Tribe to the US Supreme Court.
